Clinical Trial Update: Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of ebastine with docetaxel for metastatic castration-resistant prostate cancer; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ebastine (ebastine)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING